However, with the shortage officially declared over, the FDA has set deadlines for these entities to cease compounding semaglutide injectionsApril 22, 2025, for 503A compounding pharmacies and May 22, 2025, for 503B outsourcing facilities
Patients should be aware of the signs to watch for, such as nausea, vomiting, and abdominal pain, which may necessitate a reassessment of their treatment plan
Further, oral formulations have been more associated with nausea and vomiting than others
The verdict Conditional on most plans EmblemHealth's Wegovy coverage for weight loss is employer-dependent and not publicly published in detail
If your progress still feels stalled after this period, it may be helpful to explore the reasons behind a GLP-1 plateau and how to effectively break through it
Digestive Diseases and Sciences 53(4): 11141121